Yuhan (000100.KS) Stock Price

Yuhan Price

KOSDAQ·CLOSED
83,700.00KRW+200.00 (+0.24 %)
Market closed

Over the last 19 years Yuhan grew revenue by 9.0% annually, reaching 2.07 T KRW. Earnings per share have grown at 0.3% per year over the last 19 years. For Yuhan, the net margin of 3.4% is down versus 11.7% a few years ago. At today's price the dividend yield works out to roughly 0.60%. The payout ratio is around 53% of earnings. The consensus 12-month price target for Yuhan is 151,980.00 KRW, about 81.6% above where the stock trades today. Of 20 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 28% above its 52-week low.

Yuhan stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Yuhan over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Yuhan stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Yuhan's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Yuhan Stock Price History
DateYuhan Price
8/14/202683,700.00 KRW
8/13/202683,500.00 KRW
8/12/202683,100.00 KRW
8/11/202685,300.00 KRW
8/10/202681,700.00 KRW
8/7/202680,600.00 KRW
8/6/202676,000.00 KRW
8/5/202676,200.00 KRW
8/4/202674,800.00 KRW
8/3/202674,300.00 KRW
7/31/202673,500.00 KRW
7/30/202672,150.00 KRW
7/29/202670,300.00 KRW
7/28/202670,700.00 KRW
7/27/202672,500.00 KRW
7/24/202674,900.00 KRW
7/23/202671,400.00 KRW
7/22/202670,200.00 KRW
7/21/202669,600.00 KRW
7/20/202669,800.00 KRW
7/16/202670,800.00 KRW
7/15/202669,400.00 KRW
7/14/202667,200.00 KRW
7/13/202669,500.00 KRW
7/10/202669,600.00 KRW
7/9/202667,400.00 KRW
7/8/202668,900.00 KRW
7/7/202670,300.00 KRW
7/6/202669,600.00 KRW
7/3/202669,600.00 KRW
7/2/202670,400.00 KRW
7/1/202670,000.00 KRW
6/30/202671,000.00 KRW
6/29/202672,400.00 KRW
6/26/202665,500.00 KRW
6/25/202674,100.00 KRW
6/24/202672,200.00 KRW
6/23/202669,800.00 KRW
6/22/202673,400.00 KRW
6/19/202675,750.00 KRW
6/18/202677,800.00 KRW
6/17/202680,100.00 KRW
6/16/202678,600.00 KRW
6/15/202678,900.00 KRW
6/12/202678,200.00 KRW
6/11/202674,200.00 KRW
6/10/202676,900.00 KRW
6/9/202676,700.00 KRW
6/8/202672,400.00 KRW
6/5/202678,100.00 KRW
6/4/202680,600.00 KRW
6/2/202681,500.00 KRW
6/1/202683,100.00 KRW
5/29/202683,400.00 KRW
5/28/202682,900.00 KRW
5/27/202686,200.00 KRW
5/26/202686,200.00 KRW
5/22/202688,200.00 KRW
5/21/202683,900.00 KRW
5/20/202681,500.00 KRW
5/19/202681,300.00 KRW
5/18/202683,400.00 KRW
5/15/202687,600.00 KRW
5/14/202687,300.00 KRW
5/13/202684,700.00 KRW
5/12/202684,900.00 KRW
5/11/202684,600.00 KRW
5/8/202686,600.00 KRW
5/7/202688,000.00 KRW
5/6/202687,800.00 KRW
5/4/202690,500.00 KRW
4/30/202691,600.00 KRW
4/29/202693,200.00 KRW
4/28/202693,700.00 KRW
4/27/202694,100.00 KRW
4/24/202694,800.00 KRW
4/23/202694,700.00 KRW
4/22/202695,100.00 KRW
4/21/202696,500.00 KRW
4/20/202697,100.00 KRW
4/17/202697,500.00 KRW
4/16/202697,700.00 KRW
4/15/202697,200.00 KRW
4/14/202693,600.00 KRW
4/13/202692,100.00 KRW
4/10/202692,900.00 KRW
4/9/202693,800.00 KRW
4/8/202694,200.00 KRW
4/7/202691,400.00 KRW
4/6/202691,800.00 KRW
4/3/202692,800.00 KRW
3/27/2026100,400.00 KRW
3/26/202699,000.00 KRW
3/25/202698,900.00 KRW
3/24/202695,600.00 KRW
3/23/202693,500.00 KRW
3/20/2026100,300.00 KRW
3/19/202698,700.00 KRW
3/18/2026100,200.00 KRW
3/17/202699,500.00 KRW
3/16/202697,400.00 KRW
3/13/202699,300.00 KRW
3/12/202699,900.00 KRW
3/11/202698,500.00 KRW
3/9/202696,400.00 KRW
3/6/202699,300.00 KRW
3/5/202698,800.00 KRW
3/4/202692,400.00 KRW
3/3/2026106,500.00 KRW
2/27/2026110,200.00 KRW
2/26/2026110,900.00 KRW
2/25/2026113,100.00 KRW
2/24/2026113,600.00 KRW
2/23/2026113,200.00 KRW
2/20/2026111,800.00 KRW
2/19/2026112,900.00 KRW
2/13/2026108,800.00 KRW
2/12/2026109,400.00 KRW
2/11/2026109,200.00 KRW
2/10/2026108,200.00 KRW
2/9/2026107,300.00 KRW
2/6/2026104,800.00 KRW
2/5/2026107,400.00 KRW
2/4/2026108,800.00 KRW
2/3/2026108,100.00 KRW
2/2/2026104,600.00 KRW
1/30/2026108,000.00 KRW
1/29/2026110,200.00 KRW
1/28/2026109,700.00 KRW
1/27/2026108,300.00 KRW
1/26/2026109,000.00 KRW
1/23/2026108,200.00 KRW
1/22/2026104,800.00 KRW
1/21/2026102,800.00 KRW
1/20/2026107,400.00 KRW
1/19/2026105,900.00 KRW
1/16/2026107,900.00 KRW
1/15/2026108,200.00 KRW
1/14/2026109,200.00 KRW
1/13/2026111,400.00 KRW
1/12/2026112,200.00 KRW
1/9/2026113,300.00 KRW
1/8/2026113,300.00 KRW
1/7/2026113,200.00 KRW
1/6/2026114,500.00 KRW
1/5/2026114,500.00 KRW
1/2/2026112,800.00 KRW
12/30/2025112,400.00 KRW
12/29/2025113,100.00 KRW
12/26/2025112,700.00 KRW
12/24/2025115,200.00 KRW
12/23/2025116,200.00 KRW
12/22/2025116,000.00 KRW
12/19/2025116,400.00 KRW
12/18/2025114,100.00 KRW
12/17/2025114,300.00 KRW
12/16/2025115,100.00 KRW
12/15/2025116,700.00 KRW
12/12/2025117,000.00 KRW
12/11/2025116,000.00 KRW
12/10/2025115,900.00 KRW
12/9/2025116,500.00 KRW
12/8/2025116,100.00 KRW
12/5/2025117,300.00 KRW
12/4/2025118,400.00 KRW
12/3/2025119,400.00 KRW
12/2/2025120,000.00 KRW
12/1/2025121,900.00 KRW
11/28/2025122,000.00 KRW
11/27/2025120,200.00 KRW
11/26/2025119,400.00 KRW
11/25/2025114,500.00 KRW
11/24/2025115,200.00 KRW
11/21/2025116,700.00 KRW
11/20/2025118,700.00 KRW
11/19/2025116,000.00 KRW
11/18/2025119,900.00 KRW
11/17/2025123,000.00 KRW
11/14/2025125,000.00 KRW
11/13/2025121,300.00 KRW
11/11/2025112,400.00 KRW
11/10/2025114,500.00 KRW
11/7/2025115,300.00 KRW
11/6/2025114,500.00 KRW
11/5/2025116,500.00 KRW
11/4/2025120,400.00 KRW
11/3/2025118,100.00 KRW
10/31/2025118,000.00 KRW
10/30/2025116,000.00 KRW
10/29/2025117,200.00 KRW
10/28/2025119,500.00 KRW
10/27/2025119,500.00 KRW
10/24/2025114,100.00 KRW
10/23/2025115,500.00 KRW
10/22/2025118,400.00 KRW
10/21/2025118,200.00 KRW
10/20/2025117,900.00 KRW
10/17/2025116,700.00 KRW
10/16/2025116,800.00 KRW
10/15/2025117,200.00 KRW
10/14/2025120,000.00 KRW
10/13/2025118,400.00 KRW
10/10/2025120,700.00 KRW
10/2/2025119,900.00 KRW
10/1/2025119,800.00 KRW
9/30/2025119,100.00 KRW
9/29/2025116,300.00 KRW
9/26/2025114,700.00 KRW
9/25/2025118,000.00 KRW
9/24/2025120,100.00 KRW
9/23/2025123,100.00 KRW
9/22/2025123,200.00 KRW
9/19/2025118,600.00 KRW
9/18/2025117,000.00 KRW
9/17/2025116,200.00 KRW
9/16/2025119,300.00 KRW
9/15/2025119,000.00 KRW
9/12/2025119,700.00 KRW
9/11/2025118,900.00 KRW
9/10/2025119,500.00 KRW
9/9/2025119,900.00 KRW
9/8/2025121,700.00 KRW
9/5/2025119,000.00 KRW
9/4/2025118,100.00 KRW
9/3/2025118,100.00 KRW
9/2/2025114,000.00 KRW
9/1/2025112,600.00 KRW
8/29/2025113,500.00 KRW
8/28/2025115,300.00 KRW
8/27/2025116,200.00 KRW
8/26/2025116,700.00 KRW
8/25/2025116,800.00 KRW
8/22/2025115,000.00 KRW
8/21/2025113,700.00 KRW
8/20/2025113,300.00 KRW
8/19/2025113,800.00 KRW
8/18/2025113,700.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Yuhan Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
1.69 T KRW
48.60 B KRW
100.85 B KRW
Jan 1, 2022
1.78 T KRW
36.03 B KRW
93.68 B KRW
Jan 1, 2023
1.86 T KRW
57.03 B KRW
134.10 B KRW
Jan 1, 2024
2.07 T KRW
54.88 B KRW
69.59 B KRW
Jan 1, 2025 (e)
2.23 T KRW
85.25 B KRW
111.30 B KRW
Jan 1, 2026 (e)
2.34 T KRW
89.69 B KRW
132.11 B KRW
Jan 1, 2027 (e)
2.58 T KRW
98.94 B KRW
194.88 B KRW
Jan 1, 2028 (e)
2.82 T KRW
108.00 B KRW
238.94 B KRW

Yuhan Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 4:43 PM
 
REVENUET KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
2013201420152016201720182019202020212022202320242025e2026e2027e2028e
0.941.021.131.321.461.521.481.621.691.781.862.072.232.342.582.82
21.537.8310.9317.0210.713.87-2.539.424.195.224.6811.237.665.2110.319.16
31.1331.0030.1829.4929.0427.2429.1034.4731.0829.1830.4433.3433.3433.3433.3433.34
293.77315.44340.67389.44424.62413.79430.85558.42524.65518.20565.86689.39742.23780.91861.43940.31
61.8474.3985.8497.7988.7150.1312.5484.2648.6036.0357.0354.8885.2589.6998.94108.00
6.557.317.607.406.073.300.855.202.882.033.072.653.833.833.833.83
84.8689.12123.22157.63106.7156.3139.22189.20100.8593.68134.1069.59111.30132.11194.88238.94
7.085.0238.2627.93-32.31-47.23-30.34382.38-46.70-7.1143.15-48.1059.9318.7047.5122.60
1,500.001,750.002,000.001,904.761,904.761,904.761,904.76380.95380.95380.95428.57500.00500.00543.63591.07–
20.0016.6714.29-4.76–––-80.00––12.5016.67–8.738.73–
66.0065.0064.0064.0064.0061.0061.0064.0078.0473.9473.8373.7973.7973.7973.7973.79
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Yuhan generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Yuhan retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Yuhan's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Yuhan has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Yuhan's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Yuhan stock margins

The Yuhan margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Yuhan. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Yuhan.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
34.47 %
5.20 %
11.68 %
Jan 1, 2021
31.08 %
2.88 %
5.98 %
Jan 1, 2022
29.18 %
2.03 %
5.28 %
Jan 1, 2023
30.44 %
3.07 %
7.21 %
Jan 1, 2024
33.34 %
2.65 %
3.37 %
Jan 1, 2025 (e)
33.34 %
3.83 %
5.00 %
Jan 1, 2026 (e)
33.34 %
3.83 %
5.64 %
Jan 1, 2027 (e)
33.34 %
3.83 %
7.54 %

Yuhan Stock Revenue, EBIT, Earnings per Share

The Yuhan earnings per share therefore indicates how much revenue Yuhan has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
25,310.39 KRW
1,316.50 KRW
2,956.22 KRW
Jan 1, 2021
21,626.40 KRW
622.68 KRW
1,292.21 KRW
Jan 1, 2022
24,016.33 KRW
487.25 KRW
1,266.89 KRW
Jan 1, 2023
25,179.18 KRW
772.48 KRW
1,816.34 KRW
Jan 1, 2024
28,021.06 KRW
743.69 KRW
943.07 KRW
Jan 1, 2025 (e)
30,168.84 KRW
1,155.23 KRW
1,508.23 KRW
Jan 1, 2026 (e)
31,741.16 KRW
1,215.44 KRW
1,790.28 KRW
Jan 1, 2027 (e)
35,014.04 KRW
1,340.76 KRW
2,640.91 KRW

Yuhan business model & stock analysis

The Yuhan Corporation is a South Korean conglomerate that was founded on September 1, 1926, under the name "Chosun Pharmaceutical Company". The company is headquartered in Seoul and employs more than 5,000 people worldwide. History: The Yuhan Corporation started as a small company with a single product, a fish oil-based ointment called "Yuksundo". The company worked hard to improve its products and expand its market, eventually expanding into other business areas such as the production of antibiotics and diabetes treatments. In the early 1950s, the company also ventured into the research and development of other pharmaceuticals. In 1962, Yuhan became a publicly traded company and received a variety of awards in the following years, including several Korean Industrial Awards. Since its inception, the company has remained committed to improving people's lives through innovation and science. Business model: The Yuhan Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of drugs and other health products. The company also makes investments in innovative technologies and healthcare startups. Over the years, Yuhan has expanded its business through partnerships with other companies and acquisitions of companies such as LGL Holdings and SillaJen Inc. The company also engages in international business relations, such as selling its products and medications in other countries. Divisions: The Yuhan Corporation has four main business divisions: Medical Research and Development, Drug Manufacturing, Biotechnology Product Development, and Health Product Production. The first division is coordinated by Yuhan Research & Development Co. Ltd, while drug manufacturing is done by Yuhan Manufacturing Co. Ltd. Biotechnology is done by Yuhan Biomedical Research Institute, and the health product segment is handled by Yuhan Healthcare. Products: Yuhan's products are diverse and include a wide range of drugs and health products. The company is involved in the production of antibiotics, analgesics, vein treatment agents, diabetes medications, cardiovascular drugs, and other pharmaceutical products. Other products also include cosmetics, oral care products, and dermatology drugs. Some of Yuhan's well-known products include the antibiotic Ceclor, a medication for the treatment of diabetes and metabolic disorders, as well as apple-based cosmetic products. All Yuhan products are manufactured according to strict quality standards and are known for their effectiveness and safety. Conclusion: The Yuhan Corporation has evolved into a diverse and innovative company focused on the production of drugs and health products. The company has a long history with many successes and has established itself as one of the major forces in the South Korean economy over the past decades. Yuhan's mission to create better healthcare remains as relevant today as it was at the time of its founding.

Yuhan SWOT Analysis

Strengths

Yuhan Corp possesses several key strengths that contribute to its competitive advantage. These strengths include:

  • Strong brand reputation: Yuhan Corp is recognized as a leading company in its industry, known for its high-quality products and services.
  • Diverse product portfolio: The company offers a wide range of products, catering to various customer needs and market segments.
  • Strong research and development capabilities: Yuhan Corp invests significantly in R&D, allowing it to innovate and stay ahead of competitors.
  • Established distribution network: The company has an extensive distribution network, enabling efficient reach to customers and markets.

Weaknesses

Despite its strengths, Yuhan Corp also faces certain weaknesses that may hinder its growth and success. These weaknesses include:

  • Dependency on limited markets: Yuhan Corp heavily relies on a few markets for its revenue, making it vulnerable to economic fluctuations or political changes in those regions.
  • Relatively high production costs: The company's production costs are higher compared to some competitors, impacting its profitability and pricing competitiveness.
  • Limited international presence: Yuhan Corp's global market penetration is relatively limited, limiting its exposure to new growth opportunities in international markets.

Opportunities

Yuhan Corp can capitalize on various opportunities to drive future growth and expansion. These opportunities include:

  • Emerging markets: The company can explore untapped markets in emerging economies, where demand for its products and services may be growing.
  • Product diversification: Yuhan Corp can expand its product portfolio further, introducing new offerings to meet evolving customer preferences and market demands.
  • Strategic partnerships: Collaborating with industry partners or forming strategic alliances can provide Yuhan Corp with access to new technologies, markets, or resources.

Threats

Yuhan Corp faces certain threats that could pose challenges to its business performance. These threats include:

  • Intense competition: The industry in which Yuhan Corp operates is highly competitive, with numerous players vying for market share.
  • Changing regulatory environment: Evolving regulations and compliance requirements may impact the company's operations, necessitating adaptation and increased costs.
  • Technological advancements: Rapid technological advancements can lead to product obsolescence or the emergence of disruptive competitors.
  • Economic downturns: Global economic downturns or recessions can reduce consumer spending, affecting demand for Yuhan Corp's products and services.

Yuhan Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Yuhan historical P/E ratio, EBIT multiple, and P/S ratio

Yuhan annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Yuhan shares outstanding

The number of shares of Yuhan was 73.79 M in 2025. This indicates how many shares Yuhan is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
64.00 M Stocks
Jan 1, 2021
78.04 M Stocks
Jan 1, 2022
73.94 M Stocks
Jan 1, 2023
73.83 M Stocks
Jan 1, 2024
73.79 M Stocks
Jan 1, 2025 (e)
73.79 M Stocks
Jan 1, 2026 (e)
73.79 M Stocks
Jan 1, 2027 (e)
73.79 M Stocks

Yuhan stock splits

In Yuhan's history, there have been no stock splits.

Yuhan Dividend History

36 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
2026600.00KRWYTD—1×
Feb 26, 2026600.00KRW↑ 20.0%1/1
2024500.00KRW↑ 16.7%1×
2023428.57KRW↑ 12.5%1×
2022380.95KRW 0.0%1×
2021380.95KRW 0.0%1×
2020380.95KRW↓ 80.0%1×
20191,904.76KRW 0.0%1×
20181,904.76KRW 0.0%1×
20171,904.76KRW 0.0%1×
20161,904.76KRW↓ 4.8%1×

Yuhan dividend history and estimates

In 2025, Yuhan paid a dividend amounting to 500.00 KRW. Dividend means that Yuhan distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
380.95 KRW
0.00 KRW
Jan 1, 2021
380.95 KRW
0.00 KRW
Jan 1, 2022
380.95 KRW
0.00 KRW
Jan 1, 2023
428.57 KRW
0.00 KRW
Jan 1, 2024
500.00 KRW
0.00 KRW
Jan 1, 2025
500.00 KRW
0.00 KRW
Jan 1, 2026 (e)
0.00 KRW
543.63 KRW
Jan 1, 2027 (e)
0.00 KRW
591.07 KRW

Yuhan dividend payout ratio

In 2025, Yuhan had a payout ratio of 33.15%. The payout ratio indicates the percentage of the company's profits that Yuhan distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
11.13 %
Jan 1, 2021
28.08 %
Jan 1, 2022
30.07 %
Jan 1, 2023
24.78 %
Jan 1, 2024
53.02 %
Jan 1, 2025 (e)
33.15 %
Jan 1, 2026 (e)
30.37 %
Jan 1, 2027 (e)
22.38 %

Current Yuhan forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.67 %
Buy
80.00 % (16)
Hold
5.00 % (1)
Sell
15.00 % (3)
12M Price Target
151,980.00
Last Price
83,700.00
Currency
KRW
12M Return Potential
81.58 %
LTM Return
0 %

Yuhan Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/24/2024375.48KRW-497.48 BKRW-2024 Q1
2/21/2024426.34KRW-501.44 BKRW-2023 Q4
7/26/2023451.01KRW-531.98 BKRW-2023 Q2
4/27/2023352.23KRW-451.08 BKRW-2023 Q1
2/14/2023346.84KRW-473.37 BKRW-2022 Q4
10/27/2022464.29KRW-498.97 BKRW-2022 Q3
8/16/2022449.64KRW-482.59 BKRW-2022 Q2
5/16/2022359.68KRW-420.29 BKRW-2022 Q1
2/16/2022265.05KRW-469.16 BKRW-2021 Q4
10/29/2021398.32KRW-468.07 BKRW-2021 Q3

EESG©

Eulerpool ESG Scorecard© for the Yuhan stock

76/100
99
Environment
99
Social
31
Governance
E

Environment

20
Scope 1 - Direct Emissions7,756
Scope 2 - Indirect emissions from purchased energy16,818
Scope 3 - Indirect emissions within the value chain620,566
Total CO₂ emissions24,574
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees25.874
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Yuhan shareholder structure

% Name
2.35741%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.16367%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.07311%
Samsung Asset Management Co., Ltd.
Samsung Asset Management Co., Ltd.
0.81889%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
0.71250%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.40961%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
...

Yuhan Beneficial Ownership Filings (SEC 13D/G)

Free Float
83.9%
Float Shares
-
Shares Outstanding
-

Yuhan Executives and Management Board

34 members · avg. age 56 · 18 % women

WC

Mr. Wuk Je Cho (68)

Co-President, Chief Executive Officer, Director · since 2009

1.09 B KRW

Management

BL

Mr. Byeong Man Lee (65)

Vice President, Director · since 2015

620.00 M KRW
YK

Mr. Yeol Hong Kim (65)

Co-President, Director

–
YL

Ms. Yeong Mi Lee (56)

Vice President

–
YL

Mr. Yeong Rae Lee (62)

Vice President · since 2018

–
SO

Mr. Se Wung Oh (53)

Vice President

–
HY

Ms. Hyo Yeong Yim (54)

Vice President

–

Board of Directors

JL

Mr. Jeong Hui Lee (72)

Other Non-Executive Director

545.00 M KRW
SC

Mr. Seong Gil Chi (60)

Non-Executive Independent Director

–
JK

Mr. Jun Cheol Kim (59)

Non-Executive Independent Director

–
DP

Mr. Dong Jin Park (58)

Non-Executive Independent Director

–
YS

Ms. Yeong Jae Shin (57)

Non-Executive Independent Director

–

Frequently asked questions about Yuhan

The business model of Yuhan Corp revolves around its core operations in the pharmaceutical industry. As a leading South Korean company, Yuhan Corp focuses on researching, developing, manufacturing, and marketing various pharmaceutical products. Its diverse portfolio includes prescription drugs, over-the-counter medications, and medical devices. By combining innovation, cutting-edge technology, and strategic partnerships, Yuhan Corp aims to address unmet medical needs and improve the overall health and well-being of individuals. With a strong emphasis on research and development, the company continually strives to deliver high-quality and effective healthcare solutions to customers worldwide.

Yuhan Corp is primarily active in the pharmaceutical industry.

The main competitors of Yuhan Corp in the market include Hanmi Pharmaceutical Co., Ltd., CJ Healthcare Corp., and Daewoong Pharmaceutical Co., Ltd.

Yuhan Corp, a leading pharmaceutical company, has a rich and extensive history. Established in 1926, it has grown to become an integral part of the healthcare industry in South Korea. Over the years, Yuhan Corp has been committed to enhancing the well-being of individuals through innovative and high-quality healthcare products. With a diverse product portfolio covering areas such as pharmaceuticals, animal health, and personal care, Yuhan Corp has established itself as a trusted brand both domestically and internationally. Continuously adapting to market demands and leveraging its research and development capabilities, Yuhan Corp strives to contribute to the improvement of global healthcare.

Yuhan Corp has achieved several significant milestones throughout its history. Some noteworthy achievements include the successful development and launch of innovative pharmaceutical products in various therapeutic areas. The company has also established strategic partnerships with global pharmaceutical organizations, expanding its global presence and promoting international collaborations. Yuhan Corp's commitment to research and development has resulted in groundbreaking advancements and the introduction of cutting-edge technologies. Additionally, it has received recognition for its sustainable business practices and contributions to societal welfare. Overall, Yuhan Corp's remarkable milestones highlight its dedication to advancing healthcare and its continuous pursuit of excellence in the pharmaceutical industry.

Yuhan Corp is primarily present in South Korea.

Yuhan Corp represents values and corporate philosophy centered around innovation, excellence, and ethical business practices. As a leading pharmaceutical and chemical company in South Korea, Yuhan Corp strives to provide innovative solutions for various healthcare needs. With a strong commitment to research and development, the company aims to enhance the quality of life by developing and commercializing safe and effective pharmaceutical products. Yuhan Corp also emphasizes sustainability and corporate social responsibility, aiming to contribute to a healthier society and environment. With a focus on customer satisfaction and continuous improvement, Yuhan Corp remains dedicated to delivering value and advancing the healthcare industry.

Analysts currently set an average price target of 140,165.00 KRW for the Yuhan stock (median: 151,980.00 KRW), implying +67.5 % versus the latest price. The consensus is based on 20 analyst ratings.

Yuhan Analyst Price Targets 2026

22 analysts currently rate the Yuhan stock: 18 recommend buying, 1 holding and 3 selling. For 2026, analysts expect Yuhan to generate revenue of 2.34 T KRW and earnings per share of 1,790.28 KRW.

Yuhan Analyst Price Targets 2026

Converted at the current exchange rate, the Yuhan share trades at 51.17 EUR (83,700.00 KRW).

Yuhan Corporation is a South Korean company that was founded in 1926 and operates in various business sectors. The company is active in the pharmaceutical, health & wellness, and chemical industries. Pharmaceuticals Yuhan Corp primarily focuses on the development and manufacturing of innovative drugs, particularly for the treatment of cancer and neurological diseases. The company is able to effectively conduct research and development as over half of its employees work in this field. In addition to the pharmaceutical industry, the company also works as a distributor for international pharmaceutical companies such as Eli Lilly and Sanofi. Health & Wellness Yuhan Corp is also active in the health and wellness industry. The company operates a comprehensive health center and offers a variety of services and products to promote the health of customers and patients. The products offered include dietary supplements, health drinks, and personal care products. Chemicals Yuhan Corp also has a business segment for chemical products. The company produces a variety of chemicals, particularly for the manufacture of authentication concepts for the electronics industry and dyes for the textile industry. The chemical division of Yuhan aims to implement sustainable production methods to develop more environmentally-friendly solutions for the industry. In summary, Yuhan Corp is a diverse company that operates in various sectors. The company has enhanced its strategies in research and development, product development, and marketing to strengthen its presence in the global market. With a combination of expertise, technological innovation, and a commitment to sustainability, Yuhan Corp has solidified its status as a leading company in the industry and will continue to do so.

The expected revenue of Yuhan is 2.34 T KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Yuhan is 132.11 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Yuhan is currently 46.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Yuhan stock.

The price-to-sales ratio (P/S) of Yuhan is currently 2.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Yuhan stock.

The Eulerpool Quality Score for Yuhan is 5/10.

The ISIN of Yuhan is KR7000100008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Yuhan is 000100.KS. The ticker symbol is used to trade Yuhan shares on the stock exchange.

Over the past 12 months, Yuhan paid a dividend of 500.00 KRW . This corresponds to a dividend yield of about 0.60 %. For the coming 12 months, Yuhan is expected to pay a dividend of 591.07 KRW.

The current dividend yield of Yuhan is 0.60 %.

Yuhan pays a dividend, distributed in the months of , , , .

Yuhan paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 591.07 KRW are expected. This corresponds to a dividend yield of 0.71 %.

Yuhan is assigned to the 'Health' sector.

To receive the latest dividend of Yuhan from amounting to 600 KRW, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Yuhan distributed 450 KRW as dividends.

The dividends of Yuhan are distributed in KRW.

All fundamentals and in-depth analysis of Yuhan

Our stock analysis for Yuhan stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Yuhan. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Yuhan Stock
Yuhan Revenue→
Yuhan Stock
Yuhan Net Income→
Yuhan Stock
Yuhan P/E→
Yuhan Stock
Yuhan P/S→
Yuhan Stock
Yuhan EBIT→
Yuhan Stock
Yuhan Dividend→
Yuhan Stock
Yuhan Directors Dealings→
Yuhan Stock
Yuhan Stocks→
Yuhan Stock
Yuhan Market capitalization→
Yuhan Stock
Yuhan Debt→
Yuhan Stock
Yuhan Liabilities→
Yuhan Stock
Yuhan Equity→
Yuhan Stock
Yuhan AAQS→
Yuhan Stock
Yuhan Employees→
Yuhan Stock
Yuhan ROE→
Yuhan Stock
Yuhan ROA→
Yuhan Stock
Yuhan ROCE→
Yuhan Stock
Yuhan News→
Yuhan Stock
Yuhan Analyst Price Targets→

Health Stocks

Yulong Eco-MaterialsYSBYung Zip Chemical Ind CoYpsomed HoldingYungjin Pharm CoYoucare Pharmaceutical Group CoYungShin Global HoldingYonghe Medical Group CoYunkang GroupYoda PharmaceuticalsYunnan Baiyao Group CoYili Chuanning Biotechnology CoAll Stocks A–Z →